Ceva receives EU marketing authorization for Cirbloc® M Hyo
A new ready to use vaccine to protect pigs against PCV2 and Mycoplasma hyopneumoniae
5 November 2024
1 minute read
By: Ceva Animal Health (Ceva), the leading French animal health company and the 5th largest global player, present in 110 countries, recently received the European marketing authorization from the European Commission for Cirbloc® M Hyo.
The new vaccine is based on the PCV2d genotype, the most circulating one in the field and on the Mycoplasma hyopneumoniae (M.hyo) strain BA 2940 already used very successfully in Hyogen®.
PCV2 and M.hyo are two of the most frequent agents affecting pigs health. Both are primary pathogens especially involved in Porcine Respiratory Diseases Complex and can be successfully controlled by vaccination.
With a single injection of 2 mL it is possible to reach the best length of protection against the two major pathogens. Pigs being protected against PCV2 and M. hyo from 6 weeks of age until 26 weeks covering the whole fattening period.
Coupled with extended use of the Ceva Lung Program™ which measures lung lesions at the slaughterhouse, the combination product offers unparalleled opportunity for producers to improve the respiratory health.
Ceva Pig Program™, a new service will help farmers to reach optimal vaccination process through team trainings, audits and monitoring of vaccination practices on farms.
Cirbloc® M Hyo will be available in European markets in the first quarter of 2025.
